Patents by Inventor Xing Dai

Xing Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12187736
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: January 7, 2025
    Assignee: InventisBio LLC
    Inventors: Xing Dai, Yaolin Wang
  • Patent number: 12173010
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: December 24, 2024
    Assignee: INVENTISBIO CO., LTD.
    Inventors: Xing Dai, Yaolin Wang, Yueheng Jiang, Yanqin Liu, Haotao Niu, Zhenwu Wang, Zixing Han, Liangshan Tao, Jifang Weng, Zhe Shi
  • Publication number: 20240343727
    Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.
    Type: Application
    Filed: August 16, 2022
    Publication date: October 17, 2024
    Inventors: Xianhai HUANG, Younong YU, Haotao NIU, Hong YANG, Shanshan WANG, Jifang WENG, Yaolin WANG, Xing DAI
  • Patent number: 12110289
    Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: October 8, 2024
    Assignee: InventisBio Co., Ltd.
    Inventors: Xing Dai, Yaolin Wang, Yueheng Jiang, Yanqin Liu, Zhe Shi, Zhenwu Wang, Liangshan Tao, Zixing Han, Haotao Niu, Jifang Weng
  • Publication number: 20240259652
    Abstract: A method is provided that includes: obtaining playback behavior data of a video to be processed; determining, based on the playback behavior data, a target video segment in which a content segmentation point of the video is located; extracting an audio feature of the target video segment; and determining the content segmentation point from the target video segment based on the audio feature.
    Type: Application
    Filed: April 9, 2024
    Publication date: August 1, 2024
    Inventors: Zonggui SUI, Xing DAI, Lei YUAN, Wengui CAI
  • Publication number: 20240189313
    Abstract: Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 13, 2024
    Inventors: Xing DAI, Xiaomei WANG, Yanqin LIU, Yueheng JIANG, Yaolin WANG
  • Publication number: 20240170914
    Abstract: According to a first aspect, the present disclosure relates to a semiconductor sub-assembly comprising a semiconductor device comprising: a semi-insulating substrate (201); a first section (210) configured to emit light; at least a second section (220) configured to modulate light emitted by said first section (210); wherein said first section (210) and said at least second section (220) are monolithically integrated on said semi-insulating substrate (201) and have a common optical waveguide (205?); said first section (210) forms a first vertical PIN junction with a first electrode (212) and a second electrode (214) on said semi-insulating substrate (201); said second section (220) forms a second vertical PIN junction with a first electrode (222) and a second electrode (224) on said semi-insulating substrate (201); an electric resistance between said first electrode (212) of said first section (210) and said first electrode (222) of said second section (220) is superior to about 50 ohms; and an electric resis
    Type: Application
    Filed: March 21, 2022
    Publication date: May 23, 2024
    Applicant: ALMAE TECHNOLOGIES
    Inventors: Xing Dai, Hélène Debregeas
  • Publication number: 20240165088
    Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.
    Type: Application
    Filed: January 18, 2024
    Publication date: May 23, 2024
    Inventors: Xing DAI, Yueheng JIANG
  • Publication number: 20240156820
    Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.
    Type: Application
    Filed: November 22, 2023
    Publication date: May 16, 2024
    Inventors: Xing DAI, Yueheng JIANG, Yanqin LIU
  • Publication number: 20240140929
    Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.
    Type: Application
    Filed: December 22, 2021
    Publication date: May 2, 2024
    Inventors: Xing DAI, Xianhai HUANG, Hong YANG, Zixing HAN, Haotao NIU, Jifang WENG, Zhe SHI, Yanqin LIU, Yueheng JIANG, Yaolin WANG
  • Patent number: 11969425
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: April 30, 2024
    Assignee: INVENTISBIO LLC
    Inventors: Xing Dai, Yaolin Wang
  • Patent number: 11903931
    Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: February 20, 2024
    Assignee: INVENTISBIO CO., LTD.
    Inventors: Xing Dai, Yueheng Jiang
  • Publication number: 20240043442
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: July 11, 2023
    Publication date: February 8, 2024
    Inventors: Xing DAI, Yaolin WANG
  • Publication number: 20240025876
    Abstract: Provided herein are compounds, crystalline free forms, crystalline salt forms, and pharmaceutical compositions of Compound 1. Also provided are methods of preparing and methods of using the same, e.g., for inhibiting a kinase and/or for treating various diseases or disorders, such as autoimmune diseases.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 25, 2024
    Applicants: InventisBio Co., Ltd., InventisBio LLC
    Inventors: Wei LI, Yanqin LIU, Dongmei QIANG, Xiaojun WANG, Xing DAI
  • Patent number: 11865115
    Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: January 9, 2024
    Assignee: INVENTISBIO CO., LTD.
    Inventors: Xing Dai, Yueheng Jiang, Yanqin Liu
  • Publication number: 20230357233
    Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: November 9, 2023
    Inventors: Xing DAI, Hong YANG, Xianhai HUANG, Haotao NIU, Zixing HAN, Zhenwu WANG, Qiang ZHANG, Yanqin LIU, Yueheng JIANG, Liangshan TAO, Jifang WENG, Zhe SHI, Yaolin WANG
  • Publication number: 20230357260
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 9, 2023
    Inventors: Xing DAI, Yaolin WANG, Yueheng JIANG, Yanqin LIU, Haotao NIU, Zhenwu WANG, Zixing HAN, Liangshan TAO, Jifang WENG, Zhe SHI
  • Publication number: 20230339911
    Abstract: Provided herein are compounds and compositions useful for treating or preventing diseases or disorders that are modulated by thyroid hormone receptor agonists, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD).
    Type: Application
    Filed: August 27, 2020
    Publication date: October 26, 2023
    Inventors: Xing DAI, Yanqin LIU, Yueheng JIANG
  • Publication number: 20230338373
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: February 9, 2023
    Publication date: October 26, 2023
    Inventors: Xing DAI, Yaolin WANG
  • Publication number: 20230331703
    Abstract: Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylanino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-lH-indol-3-yl)pyrimidin-2 -yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.
    Type: Application
    Filed: March 21, 2023
    Publication date: October 19, 2023
    Applicant: INVENTISBIO CO., LTD.
    Inventors: Xing DAI, Yueheng JIANG